GeneNews to present at OneMedPlace Financial Forum
About GeneNews --------------
GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has patented its core platform technology, the Sentinel Principle(R), which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(R) in major areas with unmet clinical needs such as cancer, cardiovascular disease, neurological disorders and arthritis. GeneNews has developed and commercialized its first clinical test based on its core platform technology, ColonSentry(TM), a blood-based test to assess an individual's risk for colorectal cancer. For more information on GeneNews and ColonSentry(TM), visit www.genenews.com and www.colonsentry.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
%SEDAR: 00009903E
For further information: Gailina Liew, President & COO, (905) 739-2036, [email protected]; Casey Gurfinkel, (416) 815-0700 x 283, [email protected]
Share this article